ENDRA Life Sciences

ENDRA Life Sciences, Inc. develops medical imaging technology. It operates Thermo-Acoustic Enhanced UltraSound platform to enable clinicians to visualize human tissue composition, function and temperature. The company was founded on July 18, 2007 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ENDRA Life Sciences reports Q1 loss, eyes market expansion

ENDRA Life Sciences is navigating challenges in a competitive market while leveraging its strengths in innovation and strategic partnerships. The company's performance in Q1 2024 reflects progress in clinical research and regulatory alignment for its TAEUS system.

ENDRA Life Sciences charts strategic course for growth and innovation

ENDRA Life Sciences is making strategic changes to drive future growth and innovation. With a focus on regulatory alignment, clinical trials, and business strategy refinement, the company aims to enhance its market position. Despite financial challenges, ENDRA remains optimistic about its future performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of enhanced ultrasound technologies, today announced that the company will report financial results for the third quarter of 2021 on Monday, November 15, 2021 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions. Part

ENDRA Life Sciences to Report Third Quarter 2021 Financial Results on November 15, 2021

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), has recently been issued U.S. Patent 11147067 (the ‘067 patent) titled, “Method And System For Monitoring Tissue Temperature” from the United States Patent & Trademark Office. The ‘067 patent relates to a novel method and system for monitoring tissue temperature during surgical procedures using ENDRA's TAEUS® system. ENDRA expects that TAEUS® will be effecti

ENDRA Life Sciences Further Strengthens TAEUS® System Intellectual Property Protection with Issuance of 21st U.S. Patent

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that management will participate in the H.C. Wainwright 5th Annual NASH Investor Conference on Tuesday, October 12, 2021. Management will deliver a company presentation at 2:00 p.m. Eastern Time and will be available for virtual one-on-one meetings with investors throughout the day. About ENDRA Life Sciences Inc. ENDRA Life Sciences is the pioneer of T

ENDRA Life Sciences to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference

ANN ARBOR, MI / ACCESSWIRE / September 7, 2021 / ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that management will participate in two upcoming virtual investment conferences. H.C. Wainwright 23rd Annual Global Investment Conference, September 13 - 15, 2021.

ENDRA Life Sciences to Participate in Two Upcoming Investment Conferences

ENDRA Life Sciences' (NDRA) CEO Francois Michelon on Q2 2021 Results - Earnings Call Transcript

Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, MI / ACCESSWIRE / August 12, 2021 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended June 30, 2021 and provided a business update.

ENDRA Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update

ANN ARBOR, MI / ACCESSWIRE / August 2, 2021 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of enhanced ultrasound technologies, today announced that the company will report financial results for the second quarter of 2021 on Thursday, August 12, 2021 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m.

ENDRA Life Sciences to Report Second Quarter 2021 Financial Results on August 12, 2021

ANN ARBOR, MI / ACCESSWIRE / July 20, 2021 / ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that management will participate in A.G.P.'s Virtual MedTech Summer Conference on Thursday, July 29, 2021.

ENDRA Life Sciences Announces Participation in A.G.P.'s Virtual MedTech Summer Conference on July 29, 2021

ANN ARBOR, MI / ACCESSWIRE / July 7, 2021 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the strengthening of its global patent portfolio with the issuance of the 17th, 18th and 19th patents from the United States Patent & Trademark Office (USPTO) for its TAEUS® technology. These three new patents are: U.S. Patent 16231895 (the ‘895 patent) "METHOD AND SYSTEM FOR ESTIMATING FRACTIONAL FAT CONTENT OF AN OBJECT OF INTEREST" U.S. Patent 16554682 (the ‘682 patent) "METHOD AND SYSTEM FOR DETERMINING AT LEAST ONE PARAMETER OF INTEREST OF A MATERIAL" U.S. Patent 16951070 (the ‘070 patent) "THERMAL ABLATION SYSTEM AND METHOD WITH INTEGRATED THERMOACOUSTIC TEMPERATURE MEASUREMENT" "The ‘895, ‘682 and ‘070 patents support ENDRA's goal to develop applications for our proprietary TAEUS® technology in areas of high unmet need.

ENDRA Life Sciences Strengthens TAEUS(R) System Intellectual Property Protection with the Issuance of Three U.S. Patents

ANN ARBOR, MI / ACCESSWIRE / June 15, 2021 / ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced the appointment of Irina Pestrikova as Senior Director of Finance and Principal Financial Officer. In this new position, Ms.

ENDRA Life Sciences Appoints Irina Pestrikova as Senior Director of Finance, Announces Departure of CFO David Wells

ANN ARBOR, MI / ACCESSWIRE / June 9, 2021 / ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that it is expected to be added to the Russell Microcap® Index according to a preliminary list of additions posted on June 4. The addition of ENDRA to this Index will be finalized at the conclusion of the 2021 Russell indexes annual reconstitution and, if affirmed, will be effective after the U.S. market opens on June 28.

ENDRA Life Sciences Set to Join the Russell Microcap(R) Index

ENDRA Life Sciences Inc. (NDRA) CEO Francois Michelon on Q1 2021 Results - Earnings Call Transcript

Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, MI / ACCESSWIRE / May 17, 2021 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended March 31, 2021 and provided a business update.

ENDRA Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update

ANN ARBOR, MI / ACCESSWIRE / May 6, 2021 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of enhanced ultrasound technologies, today announced that the company will report financial results for the first quarter of 2021 on Monday, May 17, 2021 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast at 4:30 p.m.

ENDRA Life Sciences to Report First Quarter 2021 Financial Results on May 17, 2021

The stock price of ENDRA Life Sciences Inc (NASDAQ: NDRA) increased from $2.31 to $2.40 (up 3.9%) pre-market. This is why it happened.

NDRA Stock: From $2.31 To $2.40 (3.9% Increase) Pre-Market Explanation

ANN ARBOR, MI / ACCESSWIRE / May 4, 2021 / ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the Company has recently been issued U.S. Patent 10993624 (the ‘624 patent) "Systems And Methods For Thermoacoustic Transducer Optimization" and U.S. Patent 10996163 (the ‘163 patent) "Acoustically Isolated Thermoacoustic Imaging Probe and Process of Manufacture" from the United States Patent & Trademark Office (USPTO). The TAEUS® transducer serves to receive thermoacoustic ultrasound signals, and the '624 patent provides a tool for developing and adjusting the TAEUS® probe and its transducer functionality to maximize the amount of information extracted from a subject.

ENDRA Life Sciences Further Strengthens TAEUS(R) System's Intellectual Property Protection with Issuance of Two U.S. Patents

Natus Medical Inc

Owens & Minor

Penumbra

Apollo Medical Hlds

Here are a few MedTech stocks, Natus Medical (NTUS), Owens & Minor (OMI), ENDRA Life Sciences (NDRA), Penumbra (PEN), Apollo Medical (AMEH), which might be prudent investment choices now.

5 MedTech Outperformers With Nearly 40% or More Gain in 2021

ANN ARBOR, MI / ACCESSWIRE / April 8, 2021 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the Company's Chief Technology Officer will be making a presentation at the American Institute of Ultrasound in Medicine (AIUM) Annual Integrative Ultrasound Meeting on April 14 at 11:45 am ET. The presentation will feature an overview of ENDRA's TAEUS™ technology and its initial clinical application for the measurement of liver fat.

ENDRA Life Sciences to Present at AIUM Annual Integrative Ultrasound Meeting

ENDRA Life Sciences Inc. (NDRA) CEO Francois Michelon on Q4 2020 Results - Earnings Call Transcript

Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, MI / ACCESSWIRE / March 25, 2021 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and twelve months ended December 31, 2020 and provided a business update.

ENDRA Life Sciences Reports 2020 Fourth Quarter and Full Year Financial Results, Provides Business Update

Hepion Pharmaceuticals Inc

Hepion to include ENDRA's TAEUS Ⓡ technology in Phase 2b trial of CRV431 ANN ARBOR, MI and EDISON, NJ / ACCESSWIRE / March 18, 2021 / ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), and Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical-stage biopharmaceutical company focused on AI-driven therapeutic drug development for the treatment of NASH and liver disease, announced today the signing of a collaboration agreement to incorporate TAEUS as an add-on technology to support Hepion's patient screening and biomarker measurement during the upcoming Phase 2b study of CRV431. "We are thrilled to partner with Hepion Pharmaceuticals in the further clinical development of CRV431," said ENDRA's Chairman and Chief Executive Officer Francois Michelon.

ENDRA Life Sciences and Hepion Pharmaceuticals Partner to Drive Efficiencies in NASH Clinical Trials

ANN ARBOR, MI / ACCESSWIRE / March 17, 2021 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of enhanced ultrasound technologies, today announced that the company will report financial results for the fourth quarter of 2020 on Thursday, March 25, 2021 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast at 4:30 p.m.

ENDRA Life Sciences to Report Fourth Quarter 2020 Financial Results on March 25, 2021

The stock price of ENDRA Life Sciences Inc (NASDAQ: NDRA) is trading at over 60% pre-market today. This is why it happened.

NDRA Stock Price Increases Over 60% Pre-Market: Why It Happened

Now Has 78 Patents Issued, Filed, Licensed or in Preparation As Taeus® Commercial Launch Plans Advance ANN ARBOR, MI / ACCESSWIRE / January 13, 2021 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), has recently been issued United States Patent 10888898 (the '898 patent) entitled "Shielded Ultrasound Transducer and Imaging System Employing the Same" from the United States Patent and Trademark Office. This is the 13th U.S. patent issued to ENDRA for its TAEUS® technology.

ENDRA Life Sciences Granted 13th U.S. Patent for its TAEUS(R) Platform Technology

ANN ARBOR, MI / ACCESSWIRE / January 8, 2021 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that Chairman and CEO Francois Michelon will present at the H.C. Wainwright Virtual BioConnect 2021 Conference being held January 11-14, 2021.

News for ENDRA Life Sciences Stock (NDRA)